Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
0.8800
UNCHANGED
Streaming Delayed Price
Updated: 10:01 AM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp WT
< Previous
1
2
3
4
5
6
7
Next >
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
July 09, 2024
Via
ACCESSWIRE
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
July 08, 2024
Via
ACCESSWIRE
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
June 18, 2024
Via
ACCESSWIRE
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
June 05, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
May 23, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
May 23, 2024
Via
ACCESSWIRE
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
April 16, 2024
Via
ACCESSWIRE
Lexaria Awarded New Patents
April 02, 2024
Via
ACCESSWIRE
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
January 16, 2024
Via
ACCESSWIRE
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
May 21, 2024
Via
ACCESSWIRE
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
May 17, 2024
Via
ACCESSWIRE
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
May 08, 2024
Via
ACCESSWIRE
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
May 06, 2024
Via
ACCESSWIRE
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
April 30, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
April 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
March 14, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
March 14, 2024
Via
ACCESSWIRE
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
March 07, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
March 05, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
March 05, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
March 04, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
March 04, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
March 01, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
March 01, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
February 20, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 16, 2024
Via
ACCESSWIRE
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024
Via
ACCESSWIRE
Lexaria's Submits Investigational New Drug Application
January 30, 2024
Via
ACCESSWIRE
Lexaria Releases Annual Letter from the CEO
January 24, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
January 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.